ALPL Human

Alkaline phosphatase liver/bone/kidney isozyme, phosphoamidase, Phosphocreatine phosphatase, aalkaline phosphatase, tissue-nonspecific isozyme isoform 1, ALPL, AP-TNAP, APTNAP, HOPS, HPPA, HPPC, HPPI, HPPO, TNALP, TNAP, TNS-ALP, TNSALP.

ALPL Human Recombinant produced in HEK293 is a single, glycosylated polypeptide chain containing 493 amino acids (18-501 a.a) and having a molecular mass of 54.3kDa. ALPL is fused to a 6 amino acid His-tag at C-terminus & purified by proprietary chromatographic techniques.

HEK293.

ALPL protein solution (1mg/ml) containing Phosphate buffered saline (pH7.4) & 10% glycerol.

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Avoid multiple freeze-thaw cycles.

Specific activity is > 40,000 pmol/min/ug and is defined as the amount of enzyme that hydrolyze 1pmole of 4-Methylumbelliferyl phosphate to phosphate and 4-Methylumbelliferone per minute at pH 8.8 at 37C.

DGSLVPEKEK DPKYWRDQAQ ETLKYALELQ KLNTNVAKNV IMFLGDGMGV STVTAARILK GQLHHNPGEE TRLEMDKFPF VALSKTYNTN AQVPDSAGTA TAYLCGVKAN EGTVGVSAAT ERSRCNTTQG NEVTSILRWA KDAGKSVGIV TTTRVNHATP SAAYAHSADR DWYSDNEMPP EALSQGCKDI AYQLMHNIRD IDVIMGGGRK YMYPKNKTDV EYESDEKARG TRLDGLDLVD TWKSFKPRYK HSHFIWNRTE LLTLDPHNVD YLLGLFEPGD MQYELNRNNV TDPSLSEMVV VAIQILRKNP KGFFLLVEGG RIDHGHHEGK AKQALHEAVE MDRAIGQAGS LTSSEDTLTV VTADHSHVFT FGGYTPRGNS IFGLAPMLSD TDKKPFTAIL YGNGPGYKVV GGERENVSMV DYAHNNYQAQ SAVPLRHETH GGEDVAVFSK GPMAHLLHGV HEQNYVPHVM AYAACIGANL GHCAPAS HHHHHH.

SDS

The ALPL human recombinant, a variant of the alkaline phosphatase enzyme, has emerged as a significant focus of biomedical research due to its diverse biological functions and potential therapeutic applications. Alkaline phosphatase (ALPL) is an essential enzyme involved in various physiological processes, including bone mineralization, liver function, and immune regulation. The ALPL human recombinant, generated through recombinant DNA technology, offers a unique platform to explore the molecular complexity and therapeutic implications of this enzyme. 

Understanding the molecular characteristics of ALPL is crucial to unravel its functional diversity. ALPL belongs to a family of enzymes that hydrolyze phosphate esters under alkaline conditions. The structural features, post-translational modifications, and molecular interactions of ALPL contribute to its complexity and enable its participation in multiple biological processes.

ALPL plays diverse roles in different tissues and physiological contexts. In bone, ALPL is involved in the regulation of mineralization, ensuring proper skeletal development and maintenance. In the liver, ALPL participates in bile acid metabolism and detoxification processes. Furthermore, ALPL has been implicated in immune regulation and inflammation modulation.

The therapeutic potential of the ALPL human recombinant is vast, offering opportunities for the diagnosis, treatment, and management of various diseases. ALPL-based therapies hold promise for addressing skeletal disorders, such as hypophosphatasia, where ALPL deficiency leads to impaired bone mineralization. ALPL's involvement in liver function also presents avenues for therapeutic interventions in liver diseases. Moreover, the immunomodulatory properties of ALPL highlight its potential role in immune-related disorders.

This research aims to provide a comprehensive analysis of the ALPL human recombinant, focusing on its molecular characteristics, biological functions, and therapeutic implications. By exploring the intricate nature of ALPL, we aim to shed light on its therapeutic potential and pave the way for future research in this exciting field.